Purpose: To investigate potential associations between selected laboratory markers (CRP, LDH, albumin, sodium, hemoglobin, neutrophils, and neutrophils/lymphocytes ratio [NLR]) and outcomes in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab (BEV) plus chemotherapy. Patients and Methods: We retrospectively analyzed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with BEV + chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. Results: We showed significantly better disease control rate when CRP, albumin, hemoglobin, and NLR were within established "normal" values. In univariate analysis, normal values of CRP, LDH, albumin, sodium, hemoglobin, neutrophils, and NLR were associated with better overall survival (OS). Normal values of CRP, albumin, hemoglobin, neutrophils, and NLR were associated also with better progression-free survival (PFS). In a multivariate Cox model, normal values of LDH, albumin, and NLR were associated with significantly better OS while normal CRP, albumin, and NLR were associated with better PFS. Conclusions: LDH and sodium appear to be possible prognostic markers for BEV treatment in combination with chemotherapy in NSCLC. The parameters associated with inflammatory response (CRP, NLR, albumin, and possibly hemoglobin) appear to be promising predictive markers for this treatment combination.

Department of Pneumology and Phthisiology University hospital in Pilsen Charles University Faculty of Medicine in Pilsen Pilsen Czech Republic

Department of Surgery Charles University Faculty of Medicine in Pilsen Pilsen Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Zobrazit více v PubMed

Hong S, Tan M, Wang S. et al. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2015;141(5):909–21. PubMed PMC

Sandler A, Gray R, Perry MC. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. PubMed

Ramalingam SS, Belani CP. Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Curr Opin Oncol. 2010;22(2):79–85. PubMed

Dowlati A, Gray R, Sandler AB. et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008;14(5):1407–12. PubMed

Evans T. Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. Anticancer Res. 2012;32(11):4629–38. PubMed

Ng QS, Goh V. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. J Thorac Imaging. 2010;25(2):142–50. 2010. PubMed

Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011;117(17):3889–99. PubMed PMC

Svaton M, Fiala O, Pesek M. et al. Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib. Anticancer Res. 2014;34(12):7461–5. PubMed

Fiala O, Pesek M, Finek J. et al. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Tumour Biol. 2015;36(12):9215–22. PubMed

Svaton M, Zemanova M, Skrickova J. et al. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. Anticancer Res. 2018;38(12):6771–6782. PubMed

Fiala O, Hosek P, Pesek M. et al. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma. 2017;64(4):605–610. PubMed

Artaç M, Uysal M, Karaağaç M. et al. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. J Gastrointest Cancer. 2017;48(2):176–180. PubMed

Miyagawa Y, Yanai A, Yanagawa T. et al. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget. 2020;11(1):86–98. PubMed PMC

Nixon AB, Pang H, Starr MD. et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) Clin Cancer Res. 2013;19(24):6957–6966. PubMed PMC

Heng DY, Xie W, Regan MM. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. PubMed

Bertaut A, Truntzer C, Madkouri R. et al. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget. 2016;7(43):70948–70958. PubMed PMC

Farolfi A, Petrone M, Scarpi E. et al. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24) Target Oncol. 2018;13(4):469–479. PubMed

Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–47. PubMed

Zarzecka M, Kubicki P, Kozielski J. Hyponatraemia - evaluation of prevalence in patients hospitalized in the Pulmonary Department and prognostic significance in lung cancer patients. Pneumonol Alergol Pol. 2014;82(1):18–24. PubMed

Feng W, Wang Y, Zhu X. Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients. Ann Transl Med. 2019;7(7):133. PubMed PMC

Hoang T, Dahlberg SE, Sandler AB. et al. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012;7(9):1361–1368. PubMed PMC

Li B, Li C, Guo M. et al. Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. Onco Targets Ther. 2018;11:6287–6294. PubMed PMC

Silvestris N, Scartozzi M, Graziano G. et al. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther. 2015;15(2):155–162. PubMed

Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. PubMed

Azuma M, Shi M, Danenberg KD. et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007;8(12):1705–13. PubMed

Giampieri R, Puzzoni M, Daniele B. et al. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. Br J Cancer. 2017;117(8):1099–1104. PubMed PMC

Martino EC, Misso G, Pastina P. et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016;2:16025. PubMed PMC

Casadei-Gardini A, Scarpi E, Ulivi P. et al. Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. Cancer Manag Res. 2019;11:4357–4369. PubMed PMC

Clarke SJ, Burge M, Feeney K. et al. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] PLoS One. 2020;15(3):e0229900. PubMed PMC

Cetin B, Kaplan MA, Berk V. et al. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac J Cancer Prev. 2012;13(3):1059–1063. PubMed

Harshman LC, Kuo CJ, Wong BY. et al. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest. 2009;27(8):851–856. PubMed

Botta C, Barbieri V, Ciliberto D. et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther. 2013;14(6):469–475. PubMed PMC

Fraenkel PG. Anemia of Inflammation: A Review. Med Clin North Am. 2017;101(2):285–296. PubMed PMC

Macciò A, Madeddu C, Gramignano G. et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100(1):124–32. PubMed PMC

Dogan E, Bozkurt O, Sakalar T. et al. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer. J BUON. 2019;24(5):1861–1869. PubMed

Dirican A, Varol U, Kucukzeybek Y. et al. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev. 2014;15(12):4781–4786. PubMed

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC